Overview

ChemoCentryx has established one of the broadest chemokine-based therapeutics pipelines in the pharmaceutical industry. We are internally discovering and developing several clinical- or preclinical-stage small molecule compounds, each targeting a distinct chemokine or chemoattractant receptor. Our compounds are designed to be highly potent, to minimize off-target or chemoattractant side effects as much as possible and to be orally bioavailable for improved patient compliance, as well as ease and efficiency of manufacture.

Our lead drug candidate, Traficet-EN™ (CCX282), which targets the CCR9 chemokine receptor, recently completed a Phase II/III clinical trial for the treatment of patients with moderate-to-severe Crohn's disease. Another investigational new drug in clinical trials is CCX025 which is the second orally administered compound that inhibits the CCR9 chemokine receptor. CCX140, which targets the CCR2 chemokine receptor, recently began a Phase II trial in Type 2 diabetes. CCX354, a CCR1 antagonist, started a Phase II study in rheumatoid arthritis in December 2009. CCX168, a C5aR antagonist, began a Phase I clinical trial in January 2010. CCX832, a ChemR23 antagonist, is in the late stages of preclinical development and is expected to advance into Phase I studies in late 2010. In addition, we have several programs currently in the final stages of development candidate selection which target one of several novel chemokine or chemoattractant receptors.

^ Return to Top